IL134382A0 - Thyromimetic antiobesity agents - Google Patents
Thyromimetic antiobesity agentsInfo
- Publication number
- IL134382A0 IL134382A0 IL13438200A IL13438200A IL134382A0 IL 134382 A0 IL134382 A0 IL 134382A0 IL 13438200 A IL13438200 A IL 13438200A IL 13438200 A IL13438200 A IL 13438200A IL 134382 A0 IL134382 A0 IL 134382A0
- Authority
- IL
- Israel
- Prior art keywords
- lower alkyl
- hydrogen
- cycloalkyl
- aryl
- hydroxy
- Prior art date
Links
- 239000000883 anti-obesity agent Substances 0.000 title 1
- 229940125710 antiobesity agent Drugs 0.000 title 1
- 230000000929 thyromimetic effect Effects 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 abstract 11
- 229910052739 hydrogen Inorganic materials 0.000 abstract 5
- 239000001257 hydrogen Substances 0.000 abstract 5
- 125000004356 hydroxy functional group Chemical group O* 0.000 abstract 4
- 229910052736 halogen Inorganic materials 0.000 abstract 3
- 150000002367 halogens Chemical class 0.000 abstract 3
- 238000000034 method Methods 0.000 abstract 3
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 3
- 208000008589 Obesity Diseases 0.000 abstract 2
- 125000003118 aryl group Chemical group 0.000 abstract 2
- 229910052799 carbon Inorganic materials 0.000 abstract 2
- 150000001721 carbon Chemical group 0.000 abstract 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 abstract 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 2
- 150000002431 hydrogen Chemical group 0.000 abstract 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 2
- 235000020824 obesity Nutrition 0.000 abstract 2
- 229910052760 oxygen Inorganic materials 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 229910052717 sulfur Inorganic materials 0.000 abstract 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 abstract 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 125000004423 acyloxy group Chemical group 0.000 abstract 1
- 150000001408 amides Chemical class 0.000 abstract 1
- 229940125709 anorectic agent Drugs 0.000 abstract 1
- 239000002830 appetite depressant Substances 0.000 abstract 1
- 125000002837 carbocyclic group Chemical group 0.000 abstract 1
- 150000002148 esters Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Child & Adolescent Psychology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Valve Device For Special Equipments (AREA)
- Discharging, Photosensitive Material Shape In Electrophotography (AREA)
- Refinement Of Pig-Iron, Manufacture Of Cast Iron, And Steel Manufacture Other Than In Revolving Furnaces (AREA)
- Saccharide Compounds (AREA)
- Medicinal Preparation (AREA)
- Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
- Processes Of Treating Macromolecular Substances (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US12201599P | 1999-03-01 | 1999-03-01 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL134382A0 true IL134382A0 (en) | 2001-04-30 |
Family
ID=22400061
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL13438200A IL134382A0 (en) | 1999-03-01 | 2000-02-03 | Thyromimetic antiobesity agents |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US6344481B1 (ko) |
| EP (1) | EP1036564B1 (ko) |
| JP (1) | JP2000256190A (ko) |
| KR (1) | KR100368354B1 (ko) |
| AT (1) | ATE282410T1 (ko) |
| AU (1) | AU1635300A (ko) |
| CA (1) | CA2299972C (ko) |
| CO (1) | CO5150235A1 (ko) |
| DE (1) | DE60015831T2 (ko) |
| ES (1) | ES2233282T3 (ko) |
| HU (1) | HUP0000921A3 (ko) |
| IL (1) | IL134382A0 (ko) |
| NZ (1) | NZ503122A (ko) |
| PE (1) | PE20001539A1 (ko) |
| ZA (1) | ZA200001000B (ko) |
Families Citing this family (67)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6716810B1 (en) * | 1998-12-09 | 2004-04-06 | Eleanor Roosevelt Institute | Composition and method for regulation of body weight and associated conditions |
| US6344481B1 (en) * | 1999-03-01 | 2002-02-05 | Pfizer Inc. | Thyromimetic antiobesity agents |
| WO2002081751A2 (en) * | 2001-04-03 | 2002-10-17 | The Regents Of The University Of California | A method of increasing endogenous leptin production |
| US20070203225A1 (en) * | 2001-04-03 | 2007-08-30 | Havel Peter J | Method of increasing endogenous adiponectin production and leptin production |
| ATE486842T1 (de) * | 2002-03-12 | 2010-11-15 | Merck Sharp & Dohme | Substituierte amide |
| US6825209B2 (en) | 2002-04-15 | 2004-11-30 | Research Triangle Institute | Compounds having unique CB1 receptor binding selectivity and methods for their production and use |
| US7105526B2 (en) | 2002-06-28 | 2006-09-12 | Banyu Pharmaceuticals Co., Ltd. | Benzimidazole derivatives |
| US20040077650A1 (en) * | 2002-10-18 | 2004-04-22 | Pfizer Inc. | Cannabinoid receptor ligands and uses thereof |
| US20040122033A1 (en) * | 2002-12-10 | 2004-06-24 | Nargund Ravi P. | Combination therapy for the treatment of obesity |
| US7772188B2 (en) | 2003-01-28 | 2010-08-10 | Ironwood Pharmaceuticals, Inc. | Methods and compositions for the treatment of gastrointestinal disorders |
| CN1902177A (zh) | 2003-09-22 | 2007-01-24 | 万有制药株式会社 | 新哌啶衍生物 |
| KR20060109926A (ko) * | 2003-11-19 | 2006-10-23 | 메타베이시스 테라퓨틱스, 인크. | 새로운 인-함유 갑상선 호르몬 모방약들 |
| EP1730310A2 (en) * | 2004-03-22 | 2006-12-13 | The Regents Of The University Of California | A formulation for increasing endogenous adiponectin and leptin production |
| WO2005097127A2 (en) | 2004-04-02 | 2005-10-20 | Merck & Co., Inc. | Method of treating men with metabolic and anthropometric disorders |
| WO2006128056A2 (en) * | 2005-05-26 | 2006-11-30 | Metabasis Therapeutics, Inc. | Novel phosphinic acid-containing thyromimetics |
| MX2007014502A (es) | 2005-05-26 | 2008-02-07 | Metabasis Therapeutics Inc | Tiromimeticos para el tratamiento de enfermedades del higado graso. |
| BRPI0610580B8 (pt) | 2005-05-30 | 2021-05-25 | Banyu Pharma Co Ltd | composto derivado de piperidina |
| AU2006277253A1 (en) | 2005-08-10 | 2007-02-15 | Msd K.K. | Pyridone compound |
| AU2006282260A1 (en) | 2005-08-24 | 2007-03-01 | Msd K.K. | Phenylpyridone derivative |
| JPWO2007029847A1 (ja) | 2005-09-07 | 2009-03-19 | 萬有製薬株式会社 | 二環性芳香族置換ピリドン誘導体 |
| AU2006297443B2 (en) | 2005-09-29 | 2010-08-12 | Merck Sharp & Dohme Corp. | Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators |
| CN101291662A (zh) | 2005-10-21 | 2008-10-22 | 诺瓦提斯公司 | 肾素抑制剂和抗血脂异常剂和/或抗肥胖剂的组合 |
| WO2007049798A1 (ja) | 2005-10-27 | 2007-05-03 | Banyu Pharmaceutical Co., Ltd. | 新規ベンゾオキサチイン誘導体 |
| NZ568292A (en) | 2005-11-10 | 2011-08-26 | Msd Kk | Spiro[cyclohexane-1,1'-(3'H)-4'-azaisobenzofuran]-4-carboxamide derivatives |
| WO2007132475A1 (en) * | 2006-05-15 | 2007-11-22 | Cadila Healthcare Limited | Selective tr-beta 1 agonist |
| EP2083831B1 (en) | 2006-09-22 | 2013-12-25 | Merck Sharp & Dohme Corp. | Method of treatment using fatty acid synthesis inhibitors |
| JPWO2008038692A1 (ja) | 2006-09-28 | 2010-01-28 | 萬有製薬株式会社 | ジアリールケチミン誘導体 |
| AU2008233662B2 (en) | 2007-04-02 | 2012-08-23 | Msd K.K. | Indoledione derivative |
| US8969514B2 (en) | 2007-06-04 | 2015-03-03 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases |
| EA020466B1 (ru) | 2007-06-04 | 2014-11-28 | Синерджи Фармасьютикалз Инк. | Агонисты гуанилатциклазы, пригодные для лечения желудочно-кишечных нарушений, воспаления, рака и других заболеваний |
| AU2009220605A1 (en) | 2008-03-06 | 2009-09-11 | Msd K.K. | Alkylaminopyridine derivative |
| AU2009229860A1 (en) | 2008-03-28 | 2009-10-01 | Msd K.K. | Diarylmethylamide derivative having antagonistic activity on melanin-concentrating hormone receptor |
| EP2810951B1 (en) | 2008-06-04 | 2017-03-15 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
| US20110071129A1 (en) | 2008-06-19 | 2011-03-24 | Makoto Ando | Spirodiamine-diaryl ketoxime derivative |
| ES2624828T3 (es) | 2008-07-16 | 2017-07-17 | Synergy Pharmaceuticals Inc. | Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros |
| JPWO2010013595A1 (ja) | 2008-07-30 | 2012-01-12 | Ｍｓｄ株式会社 | ５員−５員又は５員−６員縮環シクロアルキルアミン誘導体 |
| WO2010047982A1 (en) | 2008-10-22 | 2010-04-29 | Merck Sharp & Dohme Corp. | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
| AU2009309229B2 (en) | 2008-10-27 | 2012-03-15 | Cadila Healthcare Limited | Thyroid receptor ligands |
| CA2741672A1 (en) | 2008-10-31 | 2010-05-06 | Merck Sharp & Dohme Corp. | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
| WO2010086878A2 (en) | 2009-01-09 | 2010-08-05 | Cadila Healthcare Limited | Thyroid receptor modulators |
| KR101396606B1 (ko) | 2009-04-20 | 2014-05-16 | 미쓰비시 타나베 파마 코퍼레이션 | 신규 갑상선 호르몬 β 수용체 작동약 |
| AU2011218830B2 (en) | 2010-02-25 | 2014-07-24 | Merck Sharp & Dohme Corp. | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
| US9401828B2 (en) | 2010-05-20 | 2016-07-26 | Kandou Labs, S.A. | Methods and systems for low-power and pin-efficient communications with superposition signaling codes |
| US20130156720A1 (en) | 2010-08-27 | 2013-06-20 | Ironwood Pharmaceuticals, Inc. | Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders |
| US9616097B2 (en) | 2010-09-15 | 2017-04-11 | Synergy Pharmaceuticals, Inc. | Formulations of guanylate cyclase C agonists and methods of use |
| EP3243385B1 (en) | 2011-02-25 | 2021-01-13 | Merck Sharp & Dohme Corp. | Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents |
| EA201391254A1 (ru) | 2011-03-01 | 2014-02-28 | Синерджи Фармасьютикалз Инк. | Способ получения агонистов гуанилатциклазы c |
| JP2015525782A (ja) | 2012-08-02 | 2015-09-07 | メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． | 抗糖尿病性三環式化合物 |
| CN104994848A (zh) | 2013-02-22 | 2015-10-21 | 默沙东公司 | 抗糖尿病二环化合物 |
| WO2014139388A1 (en) | 2013-03-14 | 2014-09-18 | Merck Sharp & Dohme Corp. | Novel indole derivatives useful as anti-diabetic agents |
| CA2905438A1 (en) | 2013-03-15 | 2014-09-25 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase and their uses |
| CA2905435A1 (en) | 2013-03-15 | 2014-09-25 | Synergy Pharmaceuticals Inc. | Compositions useful for the treatment of gastrointestinal disorders |
| PT3004138T (pt) | 2013-06-05 | 2024-06-18 | Bausch Health Ireland Ltd | Agonistas ultrapuros de guanilato ciclase c, método de produção e utilização dos mesmos |
| WO2015051496A1 (en) | 2013-10-08 | 2015-04-16 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
| CA2959208C (en) | 2014-08-29 | 2023-09-19 | Tes Pharma S.R.L. | Pyrimidine derivatives and their use as inhibitors of alpha-amino-beta-carboxymuconate-epsilon-semialdehyde decarboxylase |
| EP3526199B1 (en) | 2016-10-14 | 2022-04-13 | Tes Pharma S.r.l. | Inhibitors of alpha-amino-beta-carboxymuconic acid semialdehyde decarboxylase |
| JP2020500199A (ja) | 2016-11-21 | 2020-01-09 | バイキング・セラピューティクス・インコーポレイテッド | グリコーゲン蓄積症の治療方法 |
| US11072602B2 (en) | 2016-12-06 | 2021-07-27 | Merck Sharp & Dohme Corp. | Antidiabetic heterocyclic compounds |
| US10968232B2 (en) | 2016-12-20 | 2021-04-06 | Merck Sharp & Dohme Corp. | Antidiabetic spirochroman compounds |
| EP3634426A4 (en) | 2017-06-05 | 2021-04-07 | Viking Therapeutics, Inc. | COMPOSITIONS FOR THE TREATMENT OF FIBROSIS |
| CA3075877A1 (en) | 2017-09-14 | 2019-03-21 | Riken | Method for producing retinal tissues |
| US11787828B2 (en) | 2018-03-22 | 2023-10-17 | Viking Therapeutics, Inc. | Crystalline forms and methods of producing crystalline forms of a compound |
| CA3119509A1 (en) | 2018-11-20 | 2020-05-28 | Tes Pharma S.R.L | Inhibitors of alpha-amino-beta-carboxymuconic acid semialdehyde decarboxxylase |
| SG11202109855PA (en) | 2019-03-13 | 2021-10-28 | Sumitomo Dainippon Pharma Co Ltd | Method for evaluating quality of transplant neural retina, and transplant neural retina sheet |
| WO2022054925A1 (ja) | 2020-09-11 | 2022-03-17 | 国立研究開発法人理化学研究所 | 神経網膜を含む細胞凝集体とマトリクスとを含む複合体及びその製造方法 |
| US20230310614A1 (en) | 2020-09-11 | 2023-10-05 | Sumitomo Pharma Co., Ltd. | Medium for Tissue for Transplantation |
| CN118302517A (zh) | 2021-11-19 | 2024-07-05 | 国立研究开发法人理化学研究所 | 片状视网膜组织的制造方法 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5315739B2 (ko) * | 1973-10-30 | 1978-05-26 | ||
| JPS50124993A (ko) * | 1974-03-20 | 1975-10-01 | ||
| JPS5937018B2 (ja) * | 1978-06-16 | 1984-09-07 | 株式会社トクヤマ | 難燃化ポリプロピレン組成物 |
| ZA824382B (en) | 1981-07-07 | 1984-02-29 | Wyeth John & Brother Ltd | Anti-obesity agents |
| GB8501372D0 (en) * | 1985-01-18 | 1985-02-20 | Smith Kline French Lab | Chemical compounds |
| GB8519154D0 (en) | 1985-07-30 | 1985-09-04 | Ici Plc | Aromatic ethers |
| GB8714901D0 (en) | 1986-07-23 | 1987-07-29 | Ici Plc | Amide derivatives |
| GB8801306D0 (en) | 1988-01-21 | 1988-02-17 | Ici Plc | Chemical compounds |
| DK0580550T3 (da) | 1992-07-21 | 1998-02-02 | Ciba Geigy Ag | Oxamidsyrederivater som hypercholesterolæmiske midler |
| JPH0834976A (ja) * | 1994-07-25 | 1996-02-06 | Asahi Denka Kogyo Kk | 潜熱利用型蓄熱材 |
| WO1996029405A2 (en) * | 1995-03-20 | 1996-09-26 | Ligand Pharmaceuticals Incorporated | MODULATORS OF ob GENE AND SCREENING METHODS THEREFOR |
| EP0920864A1 (en) * | 1997-12-03 | 1999-06-09 | Pfizer Products Inc. | Combination therapy including a specific beta-3 agonist and an anorectic agent |
| US6344481B1 (en) * | 1999-03-01 | 2002-02-05 | Pfizer Inc. | Thyromimetic antiobesity agents |
| CN1345303A (zh) * | 1999-03-01 | 2002-04-17 | 辉瑞产品公司 | 用作甲状腺受体配体的草氨酸及衍生物 |
-
2000
- 2000-01-20 US US09/488,110 patent/US6344481B1/en not_active Expired - Fee Related
- 2000-02-03 EP EP00300830A patent/EP1036564B1/en not_active Expired - Lifetime
- 2000-02-03 IL IL13438200A patent/IL134382A0/xx unknown
- 2000-02-03 ES ES00300830T patent/ES2233282T3/es not_active Expired - Lifetime
- 2000-02-03 AT AT00300830T patent/ATE282410T1/de not_active IP Right Cessation
- 2000-02-03 DE DE60015831T patent/DE60015831T2/de not_active Expired - Fee Related
- 2000-02-11 AU AU16353/00A patent/AU1635300A/en not_active Abandoned
- 2000-02-25 JP JP2000049507A patent/JP2000256190A/ja active Pending
- 2000-02-28 PE PE2000000162A patent/PE20001539A1/es not_active Application Discontinuation
- 2000-02-28 HU HU0000921A patent/HUP0000921A3/hu unknown
- 2000-02-28 KR KR10-2000-0009860A patent/KR100368354B1/ko not_active IP Right Cessation
- 2000-02-29 ZA ZA200001000A patent/ZA200001000B/xx unknown
- 2000-02-29 CA CA002299972A patent/CA2299972C/en not_active Expired - Fee Related
- 2000-02-29 NZ NZ503122A patent/NZ503122A/en unknown
- 2000-03-01 CO CO00014834A patent/CO5150235A1/es unknown
-
2001
- 2001-10-16 US US09/978,980 patent/US6555578B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| PE20001539A1 (es) | 2001-01-08 |
| US6555578B2 (en) | 2003-04-29 |
| US6344481B1 (en) | 2002-02-05 |
| EP1036564A1 (en) | 2000-09-20 |
| HU0000921D0 (en) | 2000-04-28 |
| CO5150235A1 (es) | 2002-04-29 |
| HUP0000921A3 (en) | 2004-06-28 |
| KR100368354B1 (ko) | 2003-01-24 |
| CA2299972A1 (en) | 2000-09-01 |
| US20020035153A1 (en) | 2002-03-21 |
| EP1036564B1 (en) | 2004-11-17 |
| ZA200001000B (en) | 2001-08-29 |
| DE60015831T2 (de) | 2005-12-15 |
| DE60015831D1 (de) | 2004-12-23 |
| AU1635300A (en) | 2000-09-07 |
| CA2299972C (en) | 2003-08-19 |
| KR20010006712A (ko) | 2001-01-26 |
| JP2000256190A (ja) | 2000-09-19 |
| ATE282410T1 (de) | 2004-12-15 |
| ES2233282T3 (es) | 2005-06-16 |
| HUP0000921A2 (hu) | 2000-12-28 |
| NZ503122A (en) | 2001-11-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA200001000B (en) | Thyromimetic antiobesity agents. | |
| HUT64512A (en) | Process for preparing acetic acid derivatives containing heteroatom with lipid level reducing activity and pharmaceutical compositions containing them | |
| HK1116766A1 (en) | 5-substituted-2-phenylamino-benzamides as mek inhibitors | |
| NO933452D0 (no) | Et terapeutisk middel for parkinson's sykdom | |
| SE9701144D0 (sv) | Novel compounds, their use and preparation | |
| ATE181329T1 (de) | Substituierte dibenzooxazepin-verbindungen, pharmazeutische zusammensetzungen und verfahren zur verwendung | |
| DE60014916D1 (de) | Die Verwendung eines Benzimidazoles zur Herstellung eines Medikamentes zur Krebsvorbeugung | |
| DE69125216D1 (de) | Aminoalkanesulfonsäurederivate und pharmazeutische Zusammensetzungen davon zur Prävention oder Behandlung von Herzerkrankungen | |
| AU2342397A (en) | N-aminoalkyldibenzothiophenecarboxamides; dopamine receptor subtype specific ligands | |
| KR890011596A (ko) | 불면증 치료용 의약품의 제조에 있어서 1,4-이치환-피페리디닐 화합물의 용도 | |
| DE69707372D1 (de) | Verwendung eines Phosphorsäurediesters zur Herstellung eines Arzneimittels zur Behandlung von Akne | |
| DE68918991D1 (de) | Anwendung von Vanillin-Derivaten zur Herstellung eines Arzneimittels zur Behandlung von Herpes simplex-Infektion. | |
| ATE284684T1 (de) | Amidderivate zur behandlung neurodegenerativer erkrankungen der netzhaut | |
| BR0317263A (pt) | Ligantes alfa2delta para o tratamento de fibromialgia e outras perturbações | |
| NZ293691A (en) | Use of a medicament containing an anilide compound for treatment of type i allergic diseases | |
| DE69518706D1 (de) | Verwendung von Diphenylethanderivaten zur Herstellung eines Arzneimittels zur Behandlung von Glaukom | |
| ES2111086T3 (es) | Compuestos triciclicos anfoteros como agentes antihistaminicos y antialergicos. | |
| MX9703712A (es) | Derivados de 6-metoxi-1h-benzotriazol-5-carboxamida, sus procesos de produccion y las composiciones farmaceuticas que los contienen. | |
| ATE81465T1 (de) | Verwendung von 2-oxo-imidazolidin-derivaten zur behandlung von nierenkrankheiten. |